Quick Answer
Orchestra BioMed Holdings, Inc. reported R&D Expense of $58.19 million for fiscal year 2025.
Orchestra BioMed Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $58.19M | +35.9% |
| 2024 | $42.80M | +26.6% |
| 2023 | $33.82M | +54.1% |
| 2022 | $21.95M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.03M | +21.0% | +1.3% |
| June 30, 2025 | $13.85M | +24.5% | +2.8% |
| March 31, 2025 | $13.48M | +48.0% | +16.3% |
| September 30, 2024 | $11.60M | +35.5% | +4.2% |
| June 30, 2024 | $11.13M | +30.9% | +22.1% |
| March 31, 2024 | $9.11M | +10.4% | +6.5% |
| September 30, 2023 | $8.56M | +45.1% | +0.7% |
| June 30, 2023 | $8.50M | +69.0% | +3.0% |
- Orchestra BioMed Holdings, Inc. showed an increase of +35.9% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Orchestra BioMed Holdings, Inc.’s r&d expense has grown by 165.1% (from $21.95 million to $58.19 million).
- The most recent figure is from Orchestra BioMed Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: